Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Accentia, advocated, Alan, Amolimogene, amputation, analogue, analyzed, antagonist, antagonize, antibody, Antoni, anyof, ARB, armamentarium, ascending, assay, authoritative, Avastin, AVAX, bankruptcy, Bartlett, benign, Bey, biochemical, Biocon, Biodel, Biogen, BioMedica, Biotech, BIOVAXIDtm, Bluestone, branding, buccal, burst, carcinogencity, cervical, Chair, chaperone, Chapter, chemotherapy, Cherrington, Cofounder, Cohen, composed, Cone, consecutive, consumption, correctly, customary, Dalby, Diabetesin, diketopiperazine, diluent, Dorothy, draft, drawn, dual, dysplasia, Ecuador, emptying, encompassing, enzyme, Erbitux, escape, Evonik, exemplified, exertedmuch, exertedwithin, extrapolated, Fargo, Favrille, folded, Frank, FSPNo, gene, Genentech, Genitope, Gleevec, glioblastoma, glioma, Graduate, growing, gut, GVAXtm, harvested, Hay, Heather, hedge, Herceptin, hiring, Hirsch, histology, Hofstra, hoursafter, hypertension, Immunotherapeutic, importantly, imuunotherapy, inactivated, India, inhibitor, installation, installment, intake, Intelligence, intensification, intestinal, intracellular, Irl, irradiated, ISO, Italy, ITK, Jeffrey, Journalon, kill, leukemia, lifestyle, lizard, lymphoma, macroscopic, malignant, mantle, MBA, MD, mentioned, mg, MGI, mice, Michigan, migration, Millenium, mimic, molecular, monoclonal, MT, mucosa, Murren, muscle, myeloid, myeloma, MyVax, nausea, neoplasm, Nevada, newer, nonclinical, noncontrolling, nonprofit, nonrefundable, notwithstanding, obesity, ofEITF, Oncophage, OncoVAX, Ortho, OSI, overstatement, Owen, Oxford, partner, partnered, partnership, pathway, Paul, Phantom, Pharma, pharmacokinetic, Pharmexa, PhD, Philippe, pill, plasma, play, precursor, predominant, prepay, Provenge, pulsatile, pulse, Purdue, quantitative, radiation, ratifiedEITF, rational, reconciled, recurrent, reestablish, reportedly, resale, retention, Riesenberger, Rituxan, Roche, Roger, screening, Securitieswhich, Serono, Shaw, Sitagliptin, Spain, Specifidtm, sprayed, spread, stomach, straight, Street, sublingually, subset, surgery, survival, tablet, Tarceva, theWall, tissue, today, Torcon, toxic, tract, trained, training, transgenic, TroVax, tyrosinase, uncontrolled, underwritten, unfolded, unregulated, Upjohn, UPR, Vaccinogen, Velcade, venom, VIAjecttm, VIAtabtm, vitro, vomiting, Witte
Removed:
accumulate, Akzo, Alexander, anemia, apparent, Assuming, attributable, backache, bar, calculating, canceled, CancerVax, Cheatham, clean, cold, collaborated, compare, conclusively, Connell, consumed, core, Corixa, defer, differential, Diseasessurveyed, dislike, dividend, eliminate, experiencing, extracted, Fleming, Frederick, furniture, gastrointestinal, Harold, home, house, inflation, Jay, Jesse, Kathleen, Keltner, Kundig, learning, Lebovitz, Levy, linked, liquidity, Llew, lowered, lowering, modular, month, needle, Nobel, Nobex, notified, offsetting, oversee, pneumonia, premarket, presence, processing, producer, quantified, repaid, resigned, Restructuring, Rolf, Roth, Skyler, source, spectrum, stabilize, sued, suggesting, tailored, Therion, transport, uniformly, usage, Vical, virtually, Wendell, Zinkernagel
Filing tables
Filing exhibits
MNKD similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-117811, 333-127876, 333-137332, and 333-149049 on Form S-8 of our report (which report expresses an unqualified opinion and includes an explanatory paragraph regarding a change in the manner in which MannKind Corporation accounts for share-based compensation in 2006) dated March 14, 2008, relating to the financial statements of MannKind Corporation and of our report dated March 14, 2008 relating to the effectiveness of MannKind Corporation’s internal control over financial reporting, appearing in the Annual Report on Form 10-K of MannKind Corporation for the year ended December 31, 2007.
/s/ Deloitte & Touche LLP
Los Angeles, California
March 14, 2008
March 14, 2008